Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma

Main Article Content

Sharon Del Vecchio
Robert J Ellis

Keywords

cabozantinib, first-line therapy, metastatic renal cell carcinoma, second-line therapy

Abstract

Cabozantinib is a multi-tyrosine kinase inhibitor used for the treatment of various solid-organ tumours. It was recently approved as a first- and second-line therapeutic for the management of advanced/metastatic renal cell carcinoma based on the results of two randomised controlled trials. The phase III METEOR trial compared cabozantinib against everolimus as a second- or greater line therapy and found benefits in progression-free and overall survival, and the phase II CABOSUN trial compared cabozantinib against sunitinib as a first-line therapeutic and found benefits in terms of progression-free survival. This review briefly summarises how cabozantinib fits into current treatment paradigms for the management of advanced renal cell carcinoma.

Abstract 1145 | HTML Downloads 973 PDF Downloads 510 XML Downloads 834